Main Street Group’s Processa Pharmaceuticals PCSA Stock Holding History

Main Street Group’s Portfolio PCSA Stock Details PCSA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-4	Closed	-$209	–	839
2024 Q2	$209	Hold	4	–	–	﹤0.01%	828
2024 Q1	$235	Buy	+4	New	+$317	﹤0.01%	866

Other funds holding PCSA

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Allworth Financial Folsom, California $23.6B AUM 20.99% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

MIM

Macroview Investment Management Bethesda, Maryland $162M AUM 22.52% 1-Year Est. Return

Main Street Group's PCSA Position: Q3 2024 in Review

Main Street Group sold out of Processa Pharmaceuticals (PCSA) in Q3 2024, closing a stake of 4 shares — an estimated $209 sold.

Main Street Group first reported a position in PCSA in Q1 2024 and held it in 2 quarters. The position peaked at $235 in Q1 2024. 7 funds tracked by Wall St. Rank hold PCSA as of Q3 2024.

Main Street Group reported no remaining Processa Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
Main Street Group sold 4 Processa Pharmaceuticals shares in Q3 2024, an estimated $209.
Main Street Group first reported a position in Processa Pharmaceuticals in Q1 2024 and held it in 2 quarters.
Main Street Group's Processa Pharmaceuticals position peaked at $235 in Q1 2024.
7 funds tracked by Wall St. Rank held Processa Pharmaceuticals as of Q3 2024.

Based on Main Street Group's 13F filing for Q3 2024, filed 13 Nov 2024.